Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Neurology Today
2 Recent Gains for Patients With POMS Linked to Therapeutic, Disease Management Advancements
3 “RoAD” Score Predicts Prognosis in Relapsing-Remitting Multiple Sclerosis
4 Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis
5 Factors that influence quality of life in patients with multiple sclerosis in Saudi Arabia
6 Optical Coherence Tomography Assessment Predicts Disability Worsening in MS
7 Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
8 Electronic Patient-Reported EDSS Highly Correlates With Standard EDSS for Disability Assessment in MS
9 Racial disparities present in MS treatment, disability severity
10 Fatigue Prevalence Remains High in MS Patients, Norwegian Study Shows
11 MRI Before Pregnancy Predicts Early Postpartum MS Relapse MRI Before Pregnancy Predicts Early Postpartum MS Relapse
12 Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis
13 Restless Legs Syndrome Linked to Greater Disability, Spinal Lesions in MS
14 Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
15 #AANAM – Disease Severity, Job Loss High in Black RRMS Patients in US
16 Socioeconomic status and access to multiple sclerosis treatment in Mexico
17 Magnetic Resonance Imaging of Spinal Cord Lesions in Patients with Multiple Sclerosis in Saskatchewan, Canada
18 Imaging Techniques Could Help Predict Disease Course of Multiple Sclerosis
19 Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
20 Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
21 Neurostatus-EDSS for Pathway: Improved MS outcome assessment capabilities are now available on the VeraSci eCOA Platform
22 Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis
23 Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden
24 Ped-MSSS Provides Alternative to EDSS in Pediatric-Onset Multiple Sclerosis
25 Don’t Assume MS Causes All Changes in Patients’ Disability
26 Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE deltaT1 mapping
27 #AANAM – Research Focuses on Measuring Therapeutic Lag
28 Real World Data: How to leverage transformative data sources to reduce study costs, evaluate real world clinical outcomes
29 AB Science reports today its annual financials as of 31 December 2020 and provides an update
30 Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid
31 Function in MS May Vary Significantly Within EDSS Scores
32 Concordance Between Persons with Multiple Sclerosis and Treating Physi | PPA
33 #AANAM – Measuring Blood Proteins in SPMS Could Predict Disability
34 Expanded Disability Status Scale (EDSS) and MS
35 Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy...
36 Longitudinal analysis of disability outcomes among young people with MS
37 Expanded Disability Status Scale Identifies Disability in Patients With and Without MS
38 Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis
39 Masitinib reduces time to disability progression for patients with PPMS, non-active SPMS
40 Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
41 COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
42 Clene Reports First Quarter 2021 Operating and Financial Highlights
43 Outcome measures in MS trials require more research 'to improve clinical trial design'
44 Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
45 Tysabri Use Can Lessen Disability in RRMS Patients, Real-world...
46 Exposure to DMT May Delay Disability Accumulation in Primary Progressive MS
47 New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and
48 Switching From Injectable to Oral Therapy for Relapsing-Remitting MS
49 #ACTRIMS2021 – Benign Versus Aggressive MS – the Hunt for Clues
50 Baseline and Follow-Up MRI Predictors of Long-Term Prognosis in Pediatric MS
51 Brain MRI Finds Hispanic Patients Develop More Aggressive MS
52 Children with MS May Have More Relapses, But They Recover More Fully
53 Age Found to Be Main Driver of MS Disability, Patient Therapy Response
54 Stem Cell Transplant May Slow Disability in Multiple Sclerosis
55 Baseline patient characteristics, MS severity impact COVID-19 outcomes
56 Registration opens for European Drugs Winter and Summer Schools 2021
57 Predictive Markers of First-Line Treatment Failure in Patients with MS
58 Tyrosine Kinase Inhibitor Shows Positive Results in Slowing Slide to MS Disability
59 Clinical Characteristics, MRI Markers Predict Worsening Cognition Over 10 Years in MS
60 When It Comes to Employee Safety, 'Don't Wait' to React | By Robb Monkman – Hospitality Net
61 MS Disability Tools Validated | MedPage Today
62 Ocrelizumab demonstrates sustained benefit for MS in open-label phase of ORATORIO trial
63 Duration of disease-modifying treatment impacts disability outcomes in MS
64 EDSS goes virtual with election for student council
65 Patterns of Gray Matter Atrophy Linked to MS Disease Progression
66 Measuring Gray Matter in the Brain to Predict MS Decline
67 CSF UCH-L1 Biomarker Predictive of Long-Term Disease Progression in MS
68 EAN 2020 – Atara’s multiple sclerosis plan slowly takes shape
69 MS Disability, Not Drug Therapy, Tied to Worse COVID-19 Outcomes
70 High-Dose Biotin Fails MS Trial, Dashing Hopes
71 Tysabri in Pediatric-onset MS Lessens Disease Activity, Reduces Relapses
72 NfL Blood Biomarker Captures Suboptimal Treatment Response in MS
73 Pregnancies, Later Menopause Tied to Progressive MS Onset Age
74 Bursaries for Western Balkan students for the 2021 European Drugs Winter School
75 Next:New Zealand Expands Patient Access to Funded MS Treatments
76 Understanding the Patient Factors Linked to Fatigue in Multiple Sclerosis
77 #MSVirtual2020
78 Motor Versus Cognitive Fatigue: Comparing Impact on QOL in MS
79 Satralizumab Reduces Risk of Severe NMOSD Relapse
80 Early Use of Ocrevus Best for Slowing PPMS Progression, Long-term...
81 AB Science today reports its revenues for the first half of 2020
82 #MSVirtual2020
83 Mesenchymal Stem Cell Transplantation in Progressive MS
84 Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
85 No Link Between Use of DMT, COVID-19 Severity in Patients With MS, Study Finds
86 Ocrevus Lowers Progression Risk in More Disabled MS Patients...
87 Calculated Treatment Response Score May Help Choose Between MS Therapies
88 Disease-Modifying Therapies Decrease Number of Patients With, Not Onset Toward, Secondary Progressive MS
89 Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting
90 Covid-19-induced changes in the management of multiple sclerosis
91 BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
92 Ocrevus May Delay by 7 Years PPMS Patients' Need for Wheelchair
93 Previous: Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial
94 Dr Jan Hillert on the Misclassification of SPMS as RRMS
95 Risk of Faster Progression in PPMS Tied to Older Age and Active...
96 Different MS Cognitive Phenotypes Could Help Guide Care
97 How Does Fatigue Relate to Overall Physical Activity and Disease-Related Disability in MS?
98 MS Disability Risk May Be Changing Over Time
99 Mitochondrial dysfunction and serum lactate as a biomarker for the progression and disability in MS and its correlation with the radiological findings
100 Antigone Now: How a 2000-Year-Old Story Comes Full Circle